메인콘텐츠 바로가기 메뉴영역 바로가기
하이로닉 로고

하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.

인터내셔널 웹사이트 →

It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.

International Website →
닫기
하이로닉 로고

하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.

US 웹사이트 →

It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.

US Website →
닫기
하이로닉 로고

하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.

EU 웹사이트 →

It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.

EU Website →
닫기
NEWS

총 242개의 게시물이 있습니다.

NEWS 목록 : 번호, 제목, 첨부, 작성일, 조회로 구성
Hironic Co., Ltd., a company specializing in aesthetic medical devices, announced on the 18th that it will showcase its new product, “MIGLOU,” at “KIMES 2026” (Korea International Medical & Hospital Equipment Show), the largest medical device exhibition in Korea. KIMES is Korea’s premier medical device exhibition, offering a comprehensive look at the latest trends and technologies in the medical industry. It is a major global medical industry event that attracts a massive number of domestic and international medical device companies, medical professionals, and buyers each year. At KIMES 2026, a variety of cutting-edge medical devices and smart healthcare technologies are scheduled to be introduced. During this exhibition, Hironic plans to capture the attention of domestic and international medical professionals and buyers by showcasing its new product 'MIGLOU' alongside its core lineup of aesthetic medical devices. MIGLOU is a device designed based on 2.45GHz Ultra-High Frequency (UHF) technology. By applying CNF (Complex Near Focusing) matching technology, it enables highly precise energy delivery to the target area. Additionally, it features a safety-focused design that utilizes a contact cooling system and built-in handpiece sensors during treatments. Its utility is further enhanced by supporting a variety of handpieces designed for both face and body care. Throughout the KIMES 2026 exhibition, Hironic plans to directly demonstrate MIGLOU's technological capabilities to medical professionals and buyers through on-site demonstrations and product consultations. Furthermore, as part of its strategy to expand into the global market, Hironic will actively seek collaborative opportunities with international medical professionals and partners, and conduct business meetings with overseas buyers. An official from Hironic stated, "MIGLOU, which we are unveiling at KIMES 2026, is a device developed to reflect the diverse needs of the aesthetic dermatology market." The official added, "Through continuous research and development, we plan to keep introducing innovative solutions that enhance satisfaction for both medical professionals and patients." Meanwhile, Hironic has been bolstering its competitiveness in the aesthetic medical device market through ongoing investments in Research and Development (R&D) and the expansion of its global distribution network. The company recently solidified its foundation for growth by securing a strategic investment from Cactus Private Equity (Cactus PE). Building on this momentum, Hironic is expected to continuously drive the development of next-generation technologies in the medical aesthetic field and further expand its presence in the global market.
2026-04-20
 HIRONIC, a company specializing in aesthetic medical devices, announced that it participated in the 'IMCAS World Congress 2026', the world's largest aesthetic medicine congress held in Paris, France, where it shared its portfolio of energy-based aesthetic devices and technological direction with global medical professionals.The IMCAS World Congress is an international conference attended by dermatologists, plastic surgeons, and medical device industry professionals from around the world. It serves as a prominent platform for active discussions and exchanges on the latest technological trends and industry developments.Operating a dedicated booth at IMCAS 2026, Hironic showcased a range of aesthetic equipment featuring various energy-based technologies, including HIFU, RF, and UHF. A key highlight was the company's approach of presenting combinable device configurations tailored to specific clinical environments and purposes, rather than limiting its focus to a single technology or device.During the event, Hironic also hosted a separate 'IMCAS VVIP Partners Meeting' to foster networking with global partners and medical professionals. At this meeting, participants exchanged views on Hironic's brand direction and potential future collaborations.Additionally, an official IMCAS program session featured a presentation on the practical field applications and clinical experiences of Hironic's SYNERJET PRO™ (export model), providing an opportunity to deepen the audience's understanding of the brand and its technology.At the booth, Hironic provided detailed demonstrations of its stable energy control technology, user-centric design approach, and user interfaces that reflect actual clinical environments. According to the company, these features garnered significant interest from a large number of international medical professionals.An official from Hironic stated, "IMCAS is a valuable platform to communicate directly with global medical professionals and to identify technological trends and market demands. Through our participation this year, we were able to share Hironic's brand identity and our vision for energy-based aesthetic device technology on the international stage." Moving forward, Hironic plans to further elevate its technological excellence and continuously strengthen its competitive edge in the aesthetic medical device sector through ongoing participation in global congresses and various networking opportunities.
2026-04-20
HIRONIC Co., Ltd. (CEO: Jin-Woo Lee), a global manufacturer of aesthetic medical devices, announced that Dr. Kibum Kim, Executive Director of the Society, delivered a lecture on HIRONIC’s V-RO Lifting at the 51st Fall Scientific Meeting of the Korean Society for Laser, Dermatology and Trichology (KSLDT), held on December 14 at the Grand InterContinental Parnas Seoul. The conference attracted approximately 4,500 medical professionals, making it one of the largest academic gatherings in Korea dedicated to laser- and energy-based dermatologic treatments. The Korean Society for Laser, Dermatology and Trichology hosts regular academic conferences each year to facilitate scientific exchange among dermatologists and related medical specialists. During the lecture, Dr. Kim introduced current trends in aesthetic lifting procedures, with a particular focus on the multi-layer targeting approach, which considers the skin’s structural layers in a comprehensive and stratified manner. Also presented during the session, V-RO Lifting is HIRONIC’s next-generation lifting device, designed to deliver high-intensity focused ultrasound (HIFU) and radiofrequency (RF) simultaneously within a single system. This integrated design supports a lifting approach that addresses both deep and superficial skin layers, aligning with the growing trend toward multi-layer targeted lifting techniques in aesthetic medicine. A HIRONIC representative stated, “Through this lecture at the Korean Society for Laser, Dermatology and Trichology, we were able to academically share both current lifting treatment trends and the technological direction of combining HIFU and RF. HIRONIC will continue to actively engage in academic conferences and scientific activities to communicate closely with medical professionals and contribute to the advancement of aesthetic technologies.”​ 
2025-12-17
HIRONIC Co., Ltd. (CEO: Jinwoo Lee), a global manufacturer and supplier of aesthetic medical devices, announced that its HIFU-based lifting system, NEW DOUBLO 2.0 (known domestically as V-RO Advance), has obtained official import approvals from key regulatory authorities in the Middle East, including the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates, the Ministry of Public Health (MOPH) of Qatar, and the Saudi Food and Drug Authority (SFDA). NEW DOUBLO 2.0 is the latest model in HIRONIC’s flagship DOUBLO HIFU series, incorporating advanced focusing technology and precise energy control algorithms to deliver stable and consistent treatment outcomes. The platform supports a versatile configuration of treatment handpieces, including HIFU, RF microneedling (RM), and RF, enabling physicians to address a wide range of clinical needs such as skin lifting, elasticity improvement, pore refinement, and skin tone enhancement. As a result, demand for the system continues to grow rapidly across global markets. In recent months, HIRONIC has conducted on-site clinical training and operational education programs for NEW DOUBLO 2.0 in both the UAE and Saudi Arabia. These programs provided local medical professionals with comprehensive instruction, ranging from in-depth explanations of core technologies to hands-on training sessions, and received strong interest and positive feedback from clinics and practitioners in the region. Following the latest import approvals, HIRONIC plans to further expand collaboration with regional partners while strengthening communication and engagement with the Middle Eastern market. “Demand for premium aesthetic treatments is growing rapidly across the Middle East,” said a representative from HIRONIC. “With consecutive import approvals in the UAE, Saudi Arabia, and Qatar, we aim to actively highlight the technological competitiveness of NEW DOUBLO 2.0 and further solidify our brand presence in the region.” Meanwhile, HIRONIC continues to expand global regulatory approvals for NEW DOUBLO 2.0, including ongoing processes in the United States (FDA) and Indonesia (KEMENKES RI), as part of its broader strategy to strengthen its global footprint. 
2025-12-16
SEOUL, Korea – Global aesthetic medical device company HIRONIC Co., Ltd. announced that a lecture featuring its latest device, SYNERJET, was held on November 16 at the 7th Annual Scientific Meeting & International Symposium of the Korean Lifting Society, hosted at COEX Convention Center in Seoul. The event convened leading domestic and international experts in lifting and skin treatment to share emerging trends and technologies. As the demand rises for non-invasive skin booster solutions that minimize damage while enhancing active ingredient delivery, HIRONIC’s SYNERJET garnered significant attention as a cutting-edge response to this trend.Dr. Sang-Hoon Lee, Medical Director of YEPPEUMJUYI Clinic, led the lecture, focusing on the key factors that determine treatment outcomes—absorption depth, skin hydration, and spray control. Highlighting the differences between conventional needle-based methods and SYNERJET’s needle-free technology, Dr. Lee presented clinical data underscoring the device’s uniform spray mechanism and efficient ingredient delivery. His insights drew strong interest from attending practitioners. SYNERJET is HIRONIC’s latest needle-free device that uses microjet technology to deliver skin boosters with minimal surface damage. The system ensures precise control and high stability, making it a versatile solution suitable for various skin conditions. Compared to existing needle-free devices, SYNERJET is highly rated for its technical precision and user safety. A HIRONIC spokesperson stated, “SYNERJET is designed to offer a delicate yet precise solution, combining safety and convenience. We will continue to strengthen our market competitiveness by collaborating with medical experts and enhancing trust in our technologies.”​ 
2025-11-20
Hironic Inc. (CEO Jinwoo Lee), a leading aesthetic medical device company, announced on the 24th that it has signed new export contracts with distributors in Singapore and Malaysia. This comes just two weeks after securing a major KRW 48.4 billion (approx. USD 35.5 million) supply agreement for its SYNERJET device in the North American market. According to a company official, “We recently signed agreements with key Asian distributors to export our flagship devices, including NEW DOUBLO 2.0 and SYNERJET. We aim to diversify our sales channels throughout Asia and increase our export ratio.” Hironic is actively expanding its supply chain to accelerate sales recovery in Asia. The company has completed construction of its second and third manufacturing plants in Osong, Chungbuk Province, enhancing its production infrastructure. This expansion is expected to improve manufacturing efficiency and ensure a stable global supply to meet rising overseas demand. The company also aims to facilitate the resumption of stock trading by demonstrating robust operational capabilities. SYNERJET, Hironic’s core product, utilizes a combination of Microjetting, Plasma, and Electroporation technologies to deliver skin booster ingredients without the use of needles. It offers the advantage of reduced pain and minimal downtime, making it highly attractive in both Asian and Western aesthetic markets. Previously, on November 10, Hironic signed a conditional supply agreement with a North American medical device distributor worth KRW 48.4 billion, approximately 1.5 times the company’s 2024 annual revenue of KRW 31.6 billion. The contract runs through October 2030 and is contingent upon obtaining U.S. FDA and Canada MDEL approvals. The company anticipates FDA clearance in the first half of next year. Under the agreement, 50% of the payment is made at the time of order, with the remaining 50% prior to shipment. Hironic is now at a pivotal point in its global expansion, driven by strategic partnerships across Asia and North America. Key challenges ahead include timely regulatory approvals, activation of local sales networks, and brand-building efforts in new international markets.​ 
2025-11-19
Hironic Inc. (CEO Jinwoo Lee), a leading manufacturer of aesthetic medical devices, announced on the 10th that it has signed a conditional supply agreement worth KRW 48.4 billion (approx. USD 35.5 million) with a newly contracted distributor for the North American market, including the United States and Canada, for its flagship product 'SYNERJET.' The agreement runs until October 8, 2030, and the total contract value represents approximately 153% of Hironic’s 2024 revenue of KRW 31.6 billion. Under the contract, 50% of the payment will be made upon order and the remaining 50% prior to shipment. The deal is conditional upon the successful acquisition of U.S. FDA and Canadian MDEL approvals, expected around April 2026. The estimated contract amount is based on the distributor's projected sales volume post-approval. SYNERJET is a needle-free injector that combines Microjetting, Plasma, and Electroporation technologies to deliver active ingredients into the skin without needles. The device is designed to minimize pain and downtime compared to conventional needle-based procedures, making it a highly appealing option in the aesthetic dermatology market. A Hironic official stated, “This marks our first contract with this North American distributor and serves as a significant milestone in our efforts to penetrate the U.S. market. We plan to actively support certification procedures and develop tailored marketing strategies in line with global expansion goals.” Hironic is currently exporting to over 50 countries worldwide and has a diverse portfolio of advanced aesthetic devices, including PICOHI, DOUBLO GOLD, and V-RO. The company is strengthening its global footprint through new branch establishments and regulatory approvals in major markets such as the U.S., Europe, and Japan.​ 
2025-11-19
SEOUL, Korea – November 1, 2025 – Hironic (CEO Jinwoo Lee), a global leader in aesthetic and medical devices, announced that it successfully held a hands-on seminar on November 1 at OgaYe Clinic, presenting its signature technologies, SYNERJET and V-RO Lifting (Export Name: New Doublo 2.0), to an audience of international healthcare professionals. This seminar aimed to share Hironic’s technological advancements and clinical expertise while providing global medical professionals an opportunity to explore practical applications of the devices. Attendees from diverse countries actively engaged in Q&A sessions, reflecting keen interest in the equipment. Dr. Jia Seok of OgaYe Clinic led the session, delivering an in-depth presentation on the mechanism, clinical utilization, and procedural strategies of the devices. Drawing from her extensive clinical experience, Dr. Seok’s lecture generated vibrant discussions and real-time insights, offering practical knowledge such as device settings and treatment tips, which were well-received. SYNERJET, a needle-free injector that uses microjet technology for rapid and even delivery of skin boosters, garnered strong attention for its efficacy and patient comfort. The subsequent session on V-RO Lifting (Export Name: New Doublo 2.0), a dual-energy system combining High-Intensity Focused Ultrasound (HIFU) and Radio Frequency (RF), captivated the audience with its adaptability across varying skin conditions. This event not only highlighted the capabilities of Korean medical aesthetics but also underscored its role in shaping global treatment standards. International attendees expressed enthusiasm about applying these innovations in their local markets, marking the seminar as a meaningful step in the globalization of Korea’s medical device industry. A Hironic representative commented, “The seminar was a valuable opportunity to demonstrate the excellence of our devices directly to global healthcare professionals,” adding, “We will continue to expand our global footprint through international seminars and KOL (Key Opinion Leader) collaborations.”​ 
2025-11-11
Seoul, South Korea – October 18, 2025 – HIRONIC Co., Ltd., a global leader in aesthetic and medical device innovation, announced the successful conclusion of its “SYNERJET X K BOOSTER Masterclass Seminar,” held on October 18. Led by Dr. Sangsoo Lee (Mirabel Clinic) and Dr. Sanghyuk Kim (Grandmedi Clinic), the event showcased best practices in delivering tailored solutions using HIRONIC’s needle-free microjet device SYNERJET in combination with K BOOSTER, a high-functionality aesthetic derma brand. The speakers shared clinical know-how based on real-world applications and synergy-driven outcomes. A key highlight of the seminar was the “K BOOSTER SHOWER” protocol—a needle-free, painless absorption method that uses SYNERJET to deliver K BOOSTER PDRN Plus Ampoule deep into the skin. This next-generation skin booster solution drew significant attention from attending medical professionals for its effectiveness and patient comfort. Developed by HIRONIC, SYNERJET is designed to deliver active ingredients through microjet spray technology without the use of needles. Its compatibility with a wide range of skin booster formulations makes it a versatile device for various clinical applications, enhancing both practitioner convenience and patient satisfaction. K BOOSTER, known for its ECM (extracellular matrix)-based active ingredients, has gained strong traction across dermatology clinics and the home care market. When paired with SYNERJET, the ampoules demonstrate enhanced absorption rates and user satisfaction. “This seminar was more than a product demonstration—it was an opportunity to validate a comprehensive solution that benefits both practitioners and patients,” said a HIRONIC spokesperson. “We will continue to build new standards in aesthetic medicine by expanding collaborations centered around SYNERJET.” The event also included live device demonstrations and hands-on sessions, helping attendees gain practical insights into skin and scalp care techniques. HIRONIC continues to lead in the aesthetic medical field by combining innovation and clinical collaboration. The company aims to foster global growth through advanced technologies and strategic partnerships.​ 
2025-10-23
Seoul, South Korea – October 13, 2025 – HIRONIC Inc. (CEO: Jinwoo Lee), a leading manufacturer of aesthetic medical devices, announced the successful completion of its ‘SYNERJET Hands-On Seminar’ held on September 30 at Classone Clinic in Seoul. The seminar aimed to deepen medical professionals’ understanding of SYNERJET and to foster clinical knowledge exchange. Reflecting the high interest in HIRONIC’s needle-free microjet technology, the event featured in-depth lectures and live demonstrations, followed by a dynamic Q&A session filled with active discussions. SYNERJET is a non-invasive device that delivers active ingredients into the skin using a high-pressure jet injection system. By eliminating the need for needles, the device minimizes pain, bruising, and bleeding while maximizing absorption efficiency—aligning perfectly with the current trend in aesthetic medicine that emphasizes both safety and efficacy. The device was met with favorable feedback from attending physicians. A HIRONIC spokesperson commented, “The seminar reaffirmed the strong interest of clinical professionals in our SYNERJET technology,” and added, “We will continue engaging with medical professionals across various regions through localized seminars, building mutual trust and reinforcing our clinical partnerships.”​ 
2025-10-13
Seoul, Korea – As aesthetic treatments become increasingly mainstream, demand for skin boosters and injection-based procedures continues to grow. In this evolving landscape, the aesthetic medicine field is turning its focus from merely achieving visible results to prioritizing safety and procedure consistency. Notably, needle-free technology has emerged as a compelling alternative, gaining traction among both practitioners and patients. This needle-free approach minimizes the psychological burden of needles for patients and enables more consistent delivery of active ingredients—regardless of the operator’s level of experience. It reduces variability in results and enhances both comfort and procedural safety, opening new frontiers in aesthetic innovation. Recently, devices utilizing needle-free microjet technology have expanded the options for skin booster applications. Among them, SYNERJET, developed by Hironic, uses a high-velocity microjet stream to deliver active substances into the skin in a completely non-invasive way. Because it does not puncture the skin, it significantly reduces the likelihood of pain, bruising, and serious vascular complications. Dr. Kim Min-cheol, Medical Director of Haoderm Clinic, commented, “Traditional needle-based procedures may lead to side effects depending on the practitioner's skill level. Patients also express concerns about pain and complications.” He added, “The market is now moving towards evaluating treatments holistically—combining visible efficacy with patient experience and procedural safety.” Dr. Kim further emphasized his clinic’s philosophy: “We strive for skin that improves every day—a better tomorrow starts today. It's our role to help patients feel that the moment they step out of our clinic.” He concluded, “The needle-free microjet method alleviates the fear associated with needle injections while enabling healthcare providers to deliver active ingredients more safely and effectively. This is not just about following trends—it’s a clinically validated, high-value technology with sustainable benefits.”​ 
2025-09-30
HIRONIC Co., Ltd. (CEO Jinwoo Lee), a leading medical aesthetic device manufacturer, announced the successful completion of its ‘V-RO Lifting (export name: New Doublo 2.0) Hands-on Seminar’ held recently in Busan, South Korea. The seminar was designed to enhance the clinical proficiency of medical professionals in the southeastern region through comprehensive training programs featuring HIRONIC’s flagship HIFU (High-Intensity Focused Ultrasound) device, ‘V-RO Lifting (New Doublo 2.0)’, and Microneedle RF technology. Dr. Hyejung Cha of Areumdawoon Clinic led the seminar with both theoretical lectures and live demonstrations on combined treatments using HIFU, RF, and Microneedle RF technologies—receiving enthusiastic feedback from participants. V-RO Lifting (New Doublo 2.0) is a next-generation lifting device that integrates HIFU and RF energies, offering precise targeting and a versatile range of cartridges to support various clinical applications. “V-RO’s dual-energy system allows for enhanced lifting effects while improving pores, skin elasticity, and texture—all with a single device,” said Dr. Cha. “This seminar was valuable in sharing practical know-how that can be directly applied in real-world clinical settings.” She further commented, “The newly released SYNERJET, based on micro-jet technology, also shows great promise for treating scars and pigmentation issues. It’s expected to significantly expand our clinical indications.” A HIRONIC spokesperson stated, “V-RO offers precision energy control and a versatile configuration for combination treatments, making it an ideal solution for diverse clinical needs. We will continue to strengthen customer understanding and trust through region-specific seminars.”​ 
2025-09-17
HIRONIC Inc. (CEO Jinwoo Lee), a leading medical aesthetics device manufacturer, announced the successful completion of its “SILKRO Seminar” held last month in Istanbul, Türkiye, in partnership with its local distributor, Nora Medikal. The seminar gathered around 80 local dermatologists, including current and potential users of SILKRO​, highlighting the device's advanced features and clinical efficacy. The event served as a platform to share real-world clinical experiences and treatment outcomes, drawing strong interest from the attending medical professionals. Key sessions of the seminar focused on the unique functionalities of SILKRO​, treatment protocols using various handpieces, and data-driven clinical outcomes. In particular, a presentation comparing the combined use of the RM and PS handpieces with competitor devices in terms of both technology and design excellence received enthusiastic attention from participants. Live demonstrations using the microneedling and plasma handpieces simulated real clinical settings, offering hands-on insights into practical device usage and treatment protocols. Detailed discussions on country-specific treatment trends and handpiece combinations provided valuable guidance and sparked engaging dialogue among attendees. A HIRONIC spokesperson commented, “The local dermatologists expressed high confidence in the safety and effectiveness of our devices. Active interaction between speakers and the audience helped strengthen both brand awareness and trust.” HIRONIC also shared its strategy to further solidify its presence in Türkiye and across Europe by expanding localized marketing efforts and continuing clinical-driven promotional activities.​ 
2025-09-08
HIRONIC Inc. (CEO Jinwoo Lee), a leading manufacturer of medical aesthetic devices, has launched “SYNERJET,” a needle-free microjet system designed to reduce pain and post-procedural discomfort in aesthetic treatments. The device delivers active ingredients into the skin using high-pressure micro air streams, offering patients a less invasive alternative to traditional injections. The development of SYNERJET addresses growing concerns among patients about the pain and bruising commonly associated with needle-based treatments. By utilizing a combination of needle-free microjet diffusion, plasma, and electroporation technology, SYNERJET enhances skin absorption while minimizing tissue trauma. This technology is gaining attention for its ability to improve recovery comfort and deliver more complete rejuvenation outcomes. Dr. Byungwook Kim, Chief Director of Seoul All-Up Dermatology Clinic, stated in a recent interview, “Demand is rapidly increasing in the aesthetic market for solutions that reduce pain and recovery time. The needle-free microjet technology is a promising response to these evolving expectations.” He added, “While traditional injection methods may vary in discomfort depending on practitioner skill, SYNERJET offers shorter treatment times and lower pain levels, resulting in higher patient satisfaction.” Experts believe this needle-free approach could serve as a suitable option for patients with needle anxiety or those requiring minimal downtime post-treatment. However, they also emphasize the importance of consulting medical professionals, as effectiveness may vary based on individual skin conditions and indications.​ 
2025-08-28
Hironic Inc. (CEO: Jinwoo Lee) announced on August 21 that it has received official medical device sales approval from the Taiwan Food and Drug Administration (TFDA) for its integrated lifting system ‘New Doublo 2.0’. The company also confirmed that Collamatrix, a top-tier distributor in Taiwan, will serve as its exclusive partner in the region. The aesthetic medical device industry is currently experiencing rapid growth driven by technological convergence and increasing preference for non-invasive procedures. According to global market research, the global aesthetic medicine market is expected to reach USD 71.62 billion by 2025, with a CAGR of 7.75%. Taiwan’s market is also expanding steadily due to its aging population and evolving beauty trends. Industry analysts forecast the Taiwanese beauty and personal care market to reach approximately USD 5.7 billion by 2027. Hironic’s expansion into Taiwan is backed by growing regional demand for advanced hybrid technologies such as HIFU (High-Intensity Focused Ultrasound) and RF (Radio Frequency). The ‘New Doublo 2.0’ combines HIFU, RF, and microneedling capabilities, offering powerful lifting results with shorter treatment time and minimal recovery burden. Taiwanese dermatologists who attended the 2024 Taiwan Symposium highlighted the device’s “multi-layer treatment advantage” and anticipated broad patient adoption. Hironic views this regulatory milestone not merely as a sales license, but as a significant example of how K-Beauty is extending beyond cosmetics into high-value medical aesthetics. The company believes the Korean aesthetic medical device sector is proving its global competitiveness in both technology and compliance. “Hironic aims to elevate its brand value in Taiwan to the highest tier,” said Sungho Lee​, Chief Marketing Officer at Hironic. “We expect the standardization and global brand power of Korean medical aesthetic devices to grow even stronger in the coming years.”​ 
2025-08-21